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We have investigated the role of vif in maedi-visna virus (MVV), a lentivirus of sheep, by studying in vitro replication of vif-deleted MVV
in several cell types, and the effects of vif deletion on in vivo infection. By measuring RT activity, we found that in comparison to wild-type
MVV, growth of vif-deleted MVV was similar in fetal ovine synovial (FOS) cells, highly attenuated in sheep choroid plexus (SCP) cells, and
not detectable in macrophages, natural target cells of MVV. Productive infection by vif-deleted MVV could not be demonstrated in sheep. An
increased mutation frequency was observed in DNA produced by endogenous reverse transcription of viral RNA in vif-deleted virions,
indicating the existence of a factor comparable in action to human APOBEC3G. These results suggest that the vif gene of MVV is essential
for infectivity and that the Vif protein protects the viral genome from enpackaged mutagenic activities.
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Maedi-visna virus (MVV), a member of the lentivirus
subfamily, causes slowly progressive meningoencephalo-
myelitis (visna) and pneumonia (maedi) of sheep (Georgs-
son, 1990). MVV predominantly infects cells of the
monocyte–macrophage lineage (Gendelman et al., 1986;
Narayan et al., 1982). In addition to the structural genes gag,
pol and env, MVV has two genes encoding the regulatory
proteins Tat and Rev and an accessory gene vif (Sonigo et
al., 1985), present in all known lentiviruses except equine
infectious anemia virus (EIAV) (Kawakami et al., 1987;
Oberste and Gonda, 1992). Vif is the only accessory gene
conserved in the small ruminant lentiviruses MVV and
caprine arthritis encephalitis virus (CAEV) (Pyper et al.,
1986; Saltarelli et al., 1990; Sonigo et al., 1985). Sequence
similarities among Vif proteins are low apart from a single
highly conserved motif (S/T)LQ(F/Y/R)LA (Oberste and0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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virus type 1 (HIV-1), deletion of any region of five or six
amino acids in Vif, except in the carboxy terminus, seems to
disrupt the function (Simon et al., 1999). The requirement
for Vif is cell-type dependent. When infected with vif-
deleted viruses, cells nonpermissive for these deficient
viruses, such as peripheral blood mononuclear cells
(PBMCs), produce virions with impaired replication in
any target cell, whereas vif-deleted viruses from permissive
cell types replicate without hindrance (Courcoul et al., 1995;
Fan and Peden, 1992; Fisher et al., 1987; Gabuzda et al.,
1992; Sodroski et al., 1986; Strebel et al., 1987). Vif
enhances virion infectivity in a poorly understood manner
(Borman et al., 1995; Sakai et al., 1993; Simon and Malim,
1996; Sova and Volsky, 1993; Von Schwedler et al., 1993).
HIV-1 lacking Vif has been reported to be up to 1000-fold
less infective than wild type (Fisher et al., 1987; Kishi et al.,
1992; Strebel et al., 1987) and the Vif protein is essential in
HIV-1 and HIV type 2 (HIV-2) (Chowdhury et al., 1996;
Courcoul et al., 1995; Fan and Peden, 1992; Gabuzda et al.,
1992, 1994; Gibbs et al., 1994a; Kawamura et al., 1994;
Michaels et al., 1993; Reddy et al., 1995), simian immuno-
deficiency virus (SIV) (Gibbs et al., 1994b; Park et al.,
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al., 1999; Tomonaga et al., 1992) and CAEV (Harmache et
al., 1995) for productive infection of cultured primary cells.
In vivo experiments with CAEV (Harmache et al., 1996),
FIV (Inoshima et al., 1996, 1998; Lockridge et al., 2000)
and SIV (Desrosiers et al., 1998) have confirmed the
requirement for a functional vif gene for effective host
infections, with delta-vif infections resulting in low viral
loads and very weak antibody responses. New investiga-
tions have shown a requirement for HIV-1 Vif protein to
counter G-to-A mutations in nascent retroviral DNA in-
duced by the APOBEC3G protein (also know as CEM15)
expressed in nonpermissive human cells (Harris et al., 2003;
Lecossier et al., 2003; Mangeat et al., 2003; Sheehy et al.,
2002; Zhang et al., 2003).
The aim of this study was to determine the importance of
the MVV vif gene in vitro by infecting several cell-types
with vif-deleted virus particles produced by sheep choroid
plexus (SCP) cells, and in vivo by intratracheal inoculation
of sheep with the same virus. In light of recent investiga-
tions, we have also determined the nature and frequency of
mutations in Vif-deficient virions.Results
Construction and identification of vif mutant viruses
The dVif-1 mutant used in this study carries a 447-bp
in-frame deletion within the vif gene of MVV, obtained by
StyI digestion (Fig. 1). This mutant lacks about two-thirds
of the wild-type Vif sequence. The cloned viral DNA wasFig. 1. Construction of dVif-1 mutant. (A) Staggered ends generated by StyI digest
protein encoded by the wild-type MVV KV1772 and the dVif-1 mutant, with brotransfected into fetal ovine synovial (FOS) cells and the
viral supernatants harvested at peak virus production and
titered in SCP cells for stocks of dVif-1 viruses. The
presence of the deletion in virus stocks was confirmed
by PCR and sequencing.
MVV vif gene is necessary for efficient viral replication in
cell culture
To determine the requirement for Vif in vitro, SCP grown
cell-free titered preparations of dVif-1 and the wild-type
virus KV1772 were used to infect FOS cells, SCP cells and
macrophages. The replication potential of dVif-1 MVV was
tested by daily monitoring of RT activity in supernatants
harvested from infected cells and comparing it to wt MVV
infections. In addition, cell cultures were inspected for cell
damage under the microscope. As shown in Fig. 2, all three
cell types allowed efficient replication of the wt virus
KV1772. Growth of dVif-1 could not be detected by RT
assay of infected macrophages (Fig. 2A). MVV Vif defi-
ciency resulted in poor growth in SCP cells (Fig. 2B) with
RT activity about 10-fold lower than with wt MVV. The
dVif-1 virus replicated in FOS cells (Fig. 2C). Microscopic
observations were consistent with these results, both dVif-1-
infected SCP cells and macrophages exhibited very little cell
damage comparable to uninfected cells, while cells infected
with wt virus showed severe cytopathic effects. dVif-1 virus
growth on FOS cells was comparable to wt virus, but
cytopathic effects were delayed by several days. These data
suggest that the Vif protein also plays an important part
during in vivo infections with MVV. To test this hypothesis,
we studied the effect of dVif-1 infections in sheep.ion were filled in and ligated. (B) Deduced amino acid sequences of the Vif
ken line indicating deletion.
Fig. 2. Analysis of dVif-1 mutant virus replication as compared to wild-type
KV1772 in macrophages (A), SCP cells (B) and FOS cells (C) following
cell-free infection. The multiplicity of infection (MOI) was 0.1. Two
independent stocks of the dVif-1 mutant were used, represented as x dVif-1
and * dVif-1. Uninfected cells were used as negative control. Samples were
taken from cell culture medium, virions pelleted by centrifugation and RT
activity measured.
Table 1







2080 10/11 1/4 5/5 2/2
2081 8/11 0/4 5/5 2/2
2082 5/11 0/4 2/5 0/2
dVif-1
2083 0/11 0/4 0/5 0/2
2084 0/11 0/4 0/5 0/2
2085 0/11 0/4 0/5 0/2
a SCP cells were used for virus culture.
b FOS and SCP cells were used for virus culture.
c Spleen, bone marrow, cervical, mediastinal, and mesenteric lymph nodes.
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To assess the ability of dVif-1 to produce in vivo
infection, three sheep (animals 2083, 2084 and 2085) were
inoculated intratracheally with dVif-1 virus. Three controlsheep (animals 2080, 2081 and 2082) were inoculated with
the wild-type virus KV1772. Blood samples were taken
before infection, at weeks 2, 3, 4, 5, 7 and 8 after infection
and then every other week until sacrifice at 18 weeks. The
blood samples were assessed for virus presence and anti-
bodies to MVV proteins. Neurovirulence was assessed by
analyzing samples of cerebrospinal fluid for cells and virus.
Several organs were assayed for virus presence. The virus
could not be isolated from any of the dVif-1 infected sheep,
neither from blood nor any of the organs tested, whereas
KV1772-inoculated sheep showed multiorgan infections.
The virus was frequently isolated from blood during the
observation period in all sheep infected with wt virus but
never in dVif-1-infected sheep (Table 1). SCP cells are
routinely used in our laboratory for propagating MVV
including co-culturing infected organs. However, because
FOS cells were more permissive for Vif-deficient MVV than
SCP cells, we also used FOS cells for attempting virus
isolation from organs. At sacrifice, the virus was isolated
from the lungs and all lymphoid organs tested from control
sheep 2080 and 2081 and from spleen and bone marrow of
sheep 2082. In sheep 2080, the virus was recovered from the
cerebrum. In repeated tests, the two dVif-1-infected sheep
2083 and 2084 showed weak antibody responses to MVV in
ELISA analysis of sera taken 16 and 18 weeks postinfection
(respectively), giving an indication of infection (Fig. 3).
These two sheep also had a faint reaction on gag-p25 viral
antigens in Western blots (data not shown). The dVif-1-
inoculated sheep 2085 was negative both in ELISA and
Western blots. The KV1772-infected controls developed
strong antibody responses as shown by ELISA (Fig. 3)
and in Western blots (data not shown).
Increased mutation frequency in Vif-deficient virions
To assess the spectrum and frequency of mutations in
dVif-1 virions, endogenous DNA synthesis was induced in
pelleted virions and a section corresponding to the capsid
protein was amplified, cloned and sequenced. Analysis of
sequences from dVif-1 virions grown in FOS and SCP cells
Fig. 4. Endogenous viral RT products were amplified, cloned and sequenced. Seq
were determined. (A) KV1772 (wt) virus passaged eight times in SCP cells. (B) d
SCP cells. The sequence of the KV1772 (wt) DNA clone is shown at the top of ea
. . .). The amino acid sequence and substitutions resulting from mutations are sho
Fig. 3. Time course of antibody response measured by ELISA. Sheep
infected with wild-type MVV KV1772, open labels; 2080 (w), 2081 (5)
and 2082 (4), and dVif-1 infected, closed labels; 2083 (x), 2084 (n) and
2085 (E). Serum dilution series were incubated with immobilized MVV
antigens and endpoints determined (A492 V 0.4).
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KV1772 (wt) grown in SCP cells (Fig. 4). G-to-A transi-
tions corresponding to cytidine deamination of the first
strand DNA were most common (13/18) as observed with
Vif-deficient HIV-1 virions (Lecossier et al., 2003; Mangeat
et al., 2003; Zhang et al., 2003). Four out of the 18
mutations were A-to-G transitions.Discussion
In this report, we demonstrate the importance of the vif
gene for MVV infectivity in vitro and in vivo. The auxiliary
gene vif, encoded by all known lentiviruses except EIAV,
has been reported to increase HIV-1 infectivity by up to
1000-fold (Fisher et al., 1987; Kishi et al., 1992; Strebel etuences from nucleotide position 961–1380 of the capsid segment of MVV
Vif-1 virus passaged once in FOS cells. (C) dVif-1 virus passaged once in
ch section and the number of clones of each sequence is indicated (1, 7,
wn above the nucleotide sequences.
Fig. 4 (continued).
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Fig. 4 (continued).
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function is still unclear. We constructed a vif-deleted
MVV mutant with an in-frame deletion of about two-thirds
of the vif gene in the infectious MVV strain KV1772 (wt).
Using RT assays to compare the replication properties of vif-
deleted mutant to wt viruses, viral production could not be
detected in cultured macrophages infected with the mutant
virus, whereas wt viruses were produced in macrophages(Fig. 2A). Macrophages are considered natural target cells
of MVV infection (Gendelman et al., 1986; Narayan et al.,
1982). These results are consistent with previous reports
showing that the active Vif protein was crucial for HIV-1
and HIV-2 infections of cultured primary cells (Chowdhury
et al., 1996; Courcoul et al., 1995; Fan and Peden, 1992;
Gabuzda et al., 1992, 1994; Gibbs et al., 1994a; Kawamura
et al., 1994; Michaels et al., 1993; Reddy et al., 1995), as
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(Lockridge et al., 1999; Tomonaga et al., 1992) and CAEV
(Harmache et al., 1995). Besides macrophages, we tested
the replication of vif-deleted MVV in two other cell-types,
SCP and FOS cells. The growth of dVif-1 was highly
attenuated in SCP cells but not in FOS cells (Figs. 2B–
C). The replication properties of vif-deleted HIV-1 have
been described for wide ranges of cell types and they have
been categorized as permissive if replication is not affected
by the Vif deficiency, or nonpermissive, if noninfectious
virions are produced by the cells. This suggests that non-
permissive cells produce a cellular factor or factors with
antiviral activity, overcome by Vif action, or the presence of
a positive factor in permissive cells, compensating Vif loss.
Heterokaryons of permissive and nonpermissive cells show
a nonpermissive phenotype, indicating the existence of an
endogenous inhibitor of HIV (Madani and Kabat, 1998;
Simon et al., 1998a). Ovine cells differ with respect to the
degree of growth of vif-deleted MVV, as exemplified by
FOS cells, which can be categorized as semipermissive and
nonpermissive SCP cells and macrophages. A possible
explanation could be the different expression of a cellular
factor interacting with Vif. Recently, a protein produced by
human nonpermissive cells but not permissive cells, APO-
BEC3G (CEM15), was reported to convert a permissive
phenotype to a nonpermissive phenotype when ectopically
expressed in permissive cells (Sheehy et al., 2002). APO-
BEC3G triggers substantial G-to-A mutations in the nascent
DNA in the absence of Vif (Harris et al., 2003; Lecossier et
al., 2003; Mangeat et al., 2003; Zhang et al., 2003).
Another example of a protein specific for nonpermissive
cells is a nuclear body protein, Sp140, reported to bind to
HIV-1 Vif. HIV-1 infection induced partial dispersal of the
protein from nuclear bodies into the cytosol where it
appeared to colocalize with Vif (Madani et al., 2002). Stable
expression of Sp140 in a permissive cell line was not
accomplished, but HeLa cells transiently expressing the
protein did not convert to a nonpermissive phenotype. It
has been reported that primate lentiviral Vif proteins func-
tion only in lymphocytes of species that are closely related
(Simon et al., 1998b). Thus, it is possible that Vif interacts
with a cellular factor that has changed during evolution of
different hosts. Thus, although Vif derived from HIV-1
counteracts human APOBEC3G action in a broad range of
retroviruses (Harris et al., 2003; Mangeat et al., 2003), this
does not hold for APOBEC3G from mouse, African Green
Monkey or rhesus macaque (Mariani et al., 2003).
Intratracheal inoculation of sheep with vif-deleted viruses
resulted in weak antibody responses as detected by ELISA
(Fig. 3). Inoculation of wt MVV resulted in multiorgan
infections, whereas sheep inoculated with vif-deleted MVV
showed no detectable viral infection in any of the tested
organs during the time course of the experiment. These
results demonstrate that the vif gene of MVV is essential for
virus infectivity in vivo. Previous reports have shown the
requirement for a functional vif gene for effective hostinfections by CAEV (Harmache et al., 1996), FIV (Inoshima
et al., 1996, 1998; Lockridge et al., 2000) and SIV (Des-
rosiers et al., 1998), and reports indicate a role for Vif in the
progression of AIDS (Alexander et al., 2002; Hassaine et
al., 2000).
Analysis of DNA produced by endogenous reverse
transcription in dVif-1 virions provides support for the
presence of a cytidine deaminase activity analogous to the
APOBEC3G protein found in Vif-deficient HIV-1 virions
(Fig. 4), although the cytidine deaminase activity in MVV
dVif-1 grown in FOS and SCP cells appears to be 10-fold
lower than in HIV-1 grown in nonpermissive cells (Lecoss-
ier et al., 2003). The observed mutation frequency of
approximately 0.1% in dVif-1 corresponds to nine muta-
tions per genome and may therefore contribute to lower
viability and infectivity. Although SCP cells are more
restrictive for growth of dVif-1 virus than FOS cells, no
difference in mutation frequency was observed. If this holds
true for all the viral genome, the substantial differences in
growth of dVif-1 viruses on SCP and FOS cells documented
here must have other explanations than an increased fre-
quency of mutations.
A notable difference in vif-deleted virions of MVV vs.
HIV-1 is that A-to-G transitions constitute a larger fraction
of the mutations, or 4/18 vs. 2/31 (Lecossier et al., 2003).
Hypermutation of A-to-G has been observed in the analysis
of spleen necrosis virus replication, suggesting a role for
adenosine deaminase acting on double-stranded RNA
(ADAR) in retroviral mutations (Kim et al., 1996). Further
support for the role of adenosine deaminases and the
involvement of secondary structures comes from analysis
of A-to-G hypermutations in human respiratory syncytial
virus (Martinez and Melero, 2002). A-to-G transitions in
MVV and HIV-1 appear to be more dispersed than hyper-
mutations described in spleen necrosis virus and human
respiratory syncitial virus and may therefore reflect a
different mechanism. It also remains to be determined
whether the A-to-G mutations observed in Vif-deficient
MVV and HIV-1 are due to a second enzymatic activity of
APOBEC3G rather than a second enzyme such as an
ADAR. It is possible that mammalian cells have developed
a range of enzymes, including cytidine and adenosine
deaminases, to destroy invading nucleic acids, and that
some of the lentiviruses have acquired and developed an
activity, the Vif protein, to counteract these defenses.Materials and methods
Molecular clone and construction of mutant
The vif-deletion mutant clone, designated dVif-1, was
constructed from the infectious wild-type molecular clone of
MVV KV1772kv72/67 (KV1772) (Andresson et al., 1993).
A plasmid subclone containing a DNA fragment from the
BamH1 site at 4587 to the HincII site at 6392 was digested
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I Klenow fragment and the blunt ends ligated. This gener-
ated a 447-bp in-frame deletion (bases 5164–5610) within
the vif gene. PCR using the forward primer 5V-CCA-
TAAGGCTACAAGGGT TGA-3V and the reverse primer
5V-TAGCCATCGTTGTAGTCTTTCG-3V was used to con-
firm mutant constructs. The following labelled primers were
used for sequencing vif in the ALFexpress (Pharmacia): 5V-
Cy5-CATACCGCCACCAAAAGAAAT-3V or 5V-Cy5-
GGGCATCCAGGAGAGTGGCAAGGA-3V.
Cells, transfections and infections
FOS cells (Andresson et al., 1993) and sheep choroid
plexus (SCP) cells (Sigurdsson et al., 1960) were grown and
maintained in Dulbecco’s minimal essential medium (Gib-
coBRL) supplemented with 2 mM glutamine, 100 IU/ml
penicillin, 100 IU/ml streptomycin and either 10% lamb
serum (growth medium) or 1% lamb serum (maintenance
medium). Cells were grown at 37 jC in a humidified
atmosphere of 5% CO2. PBMCs were isolated from healthy
sheep by sedimentation of heparinized blood diluted with
phosphate-buffered saline (PBS) on Histopaque-1077 (Sig-
ma). PBMCs obtained were treated with lysing buffer (0.14
M NH4Cl + 0.02 M Tris–HCl, pH 7.2) to lyse red blood
cells, thoroughly washed with PBS and resuspended at 12 
106 cells/ml in growth medium supplemented with 15%
lamb serum and 5  10 5 M 2-mercaptoethanol. After 24 h,
supernatant and unattached cells were removed and new
growth medium added. Adherent macrophages were grown
for 7 days before they were infected.
Transfection of FOS cells was performed with Lipofect-
amine as specified by the manufacturer (GibcoBRL). A day
after transfection, the lamb serum content was decreased
from 20% to 10% by replacing the growth medium and
again from 10% to 2% after 4 days. Viral supernatants with
maximum reverse transcription (RT) activity (harvested 21
days after transfection) were used to infect SCP cells, which
are routinely used in our laboratory for propagating MVV.
The dVif-1 clone grew to a TCID50 titer of 10
5.5/ml and
virus stocks were stored at 80 jC. Infections were carried
out at a multiplicity of infection (MOI) of 0.1 with adsorp-
tion for 4 h at 37 jC.
RT activity
Viral particles from 0.5 ml of cell-free supernatants from
infected or transfected cells were pelleted by centrifugation
at 4 jC for 1 h at 20,000  g. RT activity was determined
by using [3H]TTP (30 Ci/mmol) as previously described
(Turelli et al., 1996).
Mutations in endogenous DNA
Viral particles in 0.5 ml of cell-free supernatants were
adjusted to 50 mM Tris–HCl (pH 8.0), 10 mM MgCl2, 50units of DNAse I added and incubated at 37 jC for 30
min. Viral pellets were resuspended in 40 Al of 50 mM
Tris–HCl (pH 8.0), 4 mM MgCl2, 0.125% NP40 and 0.5
mM dNTPs, incubated at 40 jC for 120 min and heated 5
min at 90 jC. The capsid segment of MVV was amplified
with primers V919Eco: 5V-CCGGAATTCCCTATTGT-
GAATTTGCAAGC-3V and V-1578Xba: 5V-GCTCTAGAT-
TAAAATCCTTCGGATCCCAC-3V, 35 cycles of 94 jC
for 30 s, 55 jC for 20 s and 72 jC for 30 s using a
mixture of 0.4 units Taq (Amersham-Pharmacia) and 0.04
units Pfu (Stratagene) polymerases in a 40-Al reaction. The
products were gel purified (Qiaex II from Qiagen), cloned
in a Bluescript II SK vector and sequenced using BigDye
cycle sequencing ver. 1.1 (Applied Biosystems) and an
ABI 310 instrument.
Infections of sheep and tissue sampling
Icelandic sheep (8 months old) were infected by intra-
tracheal inoculation of 1.0 ml containing 1  104 TCID50 of
the appropriate MVV strain. Virus was injected into the
trachea with a needle (23G) under sedation with 0.2 ml
xylazinum i.v. (Xylapan). Blood samples were taken before
infection, at weeks 2, 3, 4, 5, 7 and 8 after infection and then
every other week until sacrifice at 18 weeks. Virus isolation
from buffy coat was performed by coculture of white blood
cells and SCP cells as previously described (Torsteinsdottir
et al., 1997) and serum samples were assayed for the
presence of virus-specific antibodies. Samples of cerebro-
spinal fluid were collected at sacrifice for cell counts and
coculture with SCP cells for virus isolation. The following
tissues were assayed for virus by coculture with SCP
(Petursson et al., 1976) and FOS cells: choroid plexus,
cerebrum, cerebellum, spleen, cervical, mediastinal and
mesenteric lymph nodes, bone marrow and lungs. Coculture
with FOS cells, in 12-well plates, was observed for 2 weeks.
If no cytopathic effects were observed, the growth medium
was passaged twice, with the last observation after 6 weeks
of culture.
ELISA analyses and Western blot
Visna virus antigen for ELISA was prepared as previ-
ously described (Torsteinsdottir et al., 1997). ELISA was
performed according to a slightly modified method from
Houwers et al. (1982) as described elsewhere (Torsteins-
dottir et al., 1997). In brief, microtiter plates (Dynatech-
Immunlon) were coated with 100 Al of 1/400 dilution of
visna ELISA antigen. Threefold serum dilutions were
made, starting with dilution 1/200. For dVif-1-infected
sheep, 2-fold serum dilutions were also made, starting
with dilution 1/50 and ending in 1/400. Unbound material
was removed by washing with PBS containing 0.05%
Tween 20. Rabbit anti-goat IgG conjugated to horseradish
peroxidase (Sigma A4174) (1/4000 dilution) was applied,
and bound antibody detected with H2O2/o-phenylenedi-
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Al of 4 M H2SO4 per well was added and the absorbance
at 492 nm read in a Perkin-Elmer HTSoft 7000Plus Bio
Assay Reader. Western blot strips were prepared using
concentrated visna virus as previously described (Tor-
steinsdottir et al., 1997). The strips were incubated with
serum samples diluted 1/200 overnight on a roller at 4 jC,
before washing in 0.1 M Tris–HCl-buffered saline, pH
7.8, containing 0.1% Tween 20 (TBS-T) for 5 min five
times. Rabbit anti-goat IgG conjugated to alkaline phos-
phatase (Sigma) diluted 1/1000 was added to each strip,
incubated for 1 h at room temperature and the strips
washed as before in TBS-T. Nitro blue tetrazolium chloride
and 5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP)
(Roche) diluted 1/50 in alkaline phosphate buffer, pH
9.5, were used to detect bound antibody.Acknowledgments
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